Aurora kinases are known to play a key role in maintaining mitotic fidelity, and overexpression of aurora kinases has been noted in various tumors. Overexpression of aurora kinase activity is thought to promote cancer development through a loss of centrosome or chromosome number integrity. Here we observed augmentation of G12V-mutated HRAS-induced neoplastic transformation in BALB/c 3T3 A31-1-1 cells transfected with Aurora-A. Aurora-A-short hairpin RNA (shRNA) experiments showed that the expression level of Aurora-A determines susceptibility to transformation. Aurora-A gene amplification was noted in human patients with tongue or gingival squamous carcinoma (4/11). Amplification was observed even in pathologically normal epithelial tissue taken at sites distant from the tumors in two patients with tongue cancer. However, overexpression of Aurora-A mRNA was observed only within the tumors of all patients examined (11/11). Our data indicate that Aurora-A gene amplification and overexpression play a role in human carcinogenesis, largely due to the effect of Aurora-A on oncogenic cell growth, rather than a loss of maintenance of centrosomal or chromosomal integrity. Keywords: oral cancer; susceptibility; polymorphism; Ras; Aurora-A Aurora kinases regulate a number of functions governing mitosis and meiosis in eucaryotes (Carmena and Earnshaw, 2003) . A single Aurora kinase, type B Aurora kinase, is present in yeast; however, mammals have three types of Aurora kinases: A, B, and C. All three kinases are overexpressed in various human tumors. In the past, overexpression of Aurora kinase activity has been thought to promote carcinogenesis by disturbing the mechanism which ensures maintenance of the normal centrosome or chromosome number, perhaps due to impairment of centrosome or centromere function, cytokinesis, or spindle checkpoint regulation (Goepfert and Brinkley, 2000; Meraldi et al., 2002; Carmena and Earnshaw, 2003) .
Among the three Aurora kinase genes, amplification of only Aurora-A (20q13.31) has been observed in human cancer cells (Sen et al., 1997) , and transfection with an Aurora-A expression vector has been reported to induce transformation of certain cell lines, such as NIH3T3 and Rat1 (Bischoff et al., 1998; Zhou et al., 1998; Ewart-Toland et al., 2003) . Thus, Aurora-A has oncogenic activity. However, the magnitude of induction of Aurora-A activity in transformed NIH3T3 cells is only 1/50-1/100 times that observed following transfection of various viral oncogenes. Moreover, repeat experiments in our laboratory revealed that BALB/c 3T3A31-1 cells transfected with an Aurora-A expression vector did not undergo malignant transformation in vitro under standard conditions. Therefore, we speculate that Aurora-A has only weak oncogenic activity on its own, and that it may, in fact, enhance the ability of other oncogenes or oncogenic signals to promote carcinogenesis.
In human carcinogenesis, augmentation of the Ras/ Raf/MEK/ERK/MAP kinase pathway-mediated cellular response to growth signals is known to occur (Davies et al., 2002) . Therefore, we performed co-transfection experiments with Aurora-A and G12V-HRAS (T24-ras) (Parada et al., 1982) , and observed that transfection with Aurora-A potentiates the frequency of G12V-HRAS-induced transformation (Figure 1a ). This result was confirmed by triplicate experiments (Figure 1b) , and was suppressed by co-transfection with a kinasenegative Aurora-A expression vector (Figure 1a and b) . Thus, we attributed the increased frequency of transformation to Aurora-A kinase activity.
Aurora A expression by BALB/c 3T3 A31-1-1 cells was seen, and greater expression levels were observed among cells that underwent G12V-HRAS-induced transformation (Figure 2a) . Therefore, the magnitude of endogenous Aurora-A expression might determine the susceptibility of BALB/c 3T3 A31-1-1 cells to G12V-HRAS-induced transformation. To examine this further, we next performed a series of Aurora-A reduced expression experiments using short hairpin RNAs (shRNAs). Several different shRNA constructs were made, and 1 mg (10 times the dosage used for the transformation-potentiation experiments) of a G12V-HRAS-carrying plasmid was co-transfected with each shRNA construct. One construct (shRNA #3) effectively reduced Aurora-A expression in G12V-HRAStransformed BALB/c 3T3 A31-1-1 cells (Figure 2b ). The #3 shRNA-transfected cells had grossly normal cell morphology (Figure 2c) , and no disruption of the cell cycle by shRNA #3 was observed (Figure 2d ). The doubling time of the #3 shRNA-transfected cells was 18 h, the same as for empty vector-transfected cells or parental 1-1ras1000 cells. Thus, this shRNA construct was able to suppress upregulation of Aurora-A expression by G12V-Ras without causing cytotoxicity, and while still enabling progression of mitosis due to residual expression of Aurora-A (Figure 2c , inset). In addition, co-transfection of the #3 shRNA construct and G12V-HRAS was observed to reduce the relative number of G12V-HRAS transfectants ( Figure 2e ). None of the other shRNA constructs resulted in suppression of G12V-Ras-induced increases in Aurora-A expression ( Figure 2f ). Thus, Aurora-A expression levels appear to be critical in determining susceptibility to G12V-HRASinduced transformation.
To examine the role of Aurora-A in human carcinogenesis, we studied patients with oral cancer. Since it was possible to distinguish areas of tongue and gingival squamous cell carcinoma from noncancerous tissue on pathological examination, noncancerous tissue was biopsied along with the tumors (Supplementary figure 3a) . Genomic DNA was then extracted from tongue or gingival squamous carcinoma tissue, along with normally appearing epithelium distant from the tumor region. Specimens from 11 patients with oral cancer (age, sex and other details are illustrated in the supplementary information) were tested by genomic Southern blot analysis using an Aurora-A-specific DNA probe. Aurora-A gene amplification was observed in 36% of the patients (4/11). In two patients, gene amplification was observed even in noncancerous tongue tissue (Figure 3a) . Regardless of the gene amplification status of noncancerous tissue, Aurora-A expression levels were greater among the tumor specimens, than normal tissue, among all patients examined. Tumor-specific transcriptional upregulation of Aurora-A was observed in all tumors, although some (patients #1, #7, #8, and #9, and HSC-4 cells) demonstrated more upregulation than others (Figure 3b ). These data indicate that Aurora-A expression levels are transcriptionally up-regulated during tongue and gingival carcinogenesis. Aurora-A gene amplification may predispose normal cells to carcinogenesis.
To clarify whether gene amplification of Aurora-A might occur under normal physiological conditions, the Aurora-A gene copy number was examined in normal lymphocytes and normal salivary gland tissue from patients in whom Aurora-A gene amplification was observed in normal tongue tissue. The blot clearly showed an absence of gene amplification in other organs (Figure 3c ), indicating that Aurora-A gene amplification Figure 1 Effect of Aurora-A on HRAS-induced transformation in vitro. Human Aurora-A cDNA was isolated from the HeLa cDNA library by RT-PCR using sense and antisense primers. T91-Aurora-A (HeLa type: WT) and its K162R mutant (kinase-negative form: K/R) were then subcloned by insertion into the KpnI/XbaI restriction site of pcDNA3 with N-terminal FLAG tagging in our laboratory. These constructs are now widely used (Katayama et al., 2004) . Expression plasmids encoding activated G12V-mutated HRAS (pSV2neo-ras (Tatsuka et al., 1996) ) were also used. A BALB/c 3T3 A31-1-1 cell transformation assay system was utilized in this study (Kakunaga et al., 1985; Tatsuka et al., 1992) . Exponentially growing cells (10 5 ) were seeded into 60-mm dishes, after which the plasmids were transfected using LipoFectamine. For the transformation-potentiation tests, 100 ng each of plasmid and empty vector were mixed together (for a total of 1 mg per dish) and applied to each dish. After 2 weeks of culture, the dishes were fixed with ethanol and stained with Giemsa solution. All experimental data were obtained from triplicate experiments. (a) Depiction of transformed foci on Giemsa-stained dishes. (b) Quantification of the number of transformed foci, as determined using standard criteria (Kakunaga et al., 1985) . The inset shows an immunoblot of cells transfected with empty vector alone (lane 1), Aurora-A(WT) (lane 2), Aurora-A(K/R) (lane 3), HRAS (lane 4), Aurora-A(WT) þ HRAS (lane 5), and Aurora-A(K/R) þ HRAS (lane 6). Cells were extracted for Western blotting as described previously (Terada et al., 1998) . Boiled and sonicated lysate was loaded onto a polyacrylamide gel. The protein was then electroblotted onto a Durapore filter (Millipore) and incubated with monoclonal anti-FLAG M5 antibody (Sigma), monoclonal anti-Ras Val12 (Sigma), or monoclonal anti-a-tubulin antibody (Cedarlane Laboratories). The immunoblot was then developed using ECL reagent (Amersham). error bars, 7 s.d. *Significant difference (Po0.001) Aurora-A and cancer susceptibility M Tatsuka et al was specific to the organ in which cancer developed. We theorize that Aurora-A gene amplification might be a consequence of long-term exposure of tongue epithelium to unknown epidemiological factor(s).
Recently, a single-nucleotide polymorphism (SNP) of Aurora-A at position 91 (T91A encoding Phe31Ile) was identified, making Aurora-A a low-penetrance tumor-susceptibility gene susceptible to amplification (Tatsuka et al., 1997) . For the detection of endogenous Aurora-A, monoclonal anti-Aurora-A antibody (BD PharMingen) was used. (b) Reduction of endogenous Aurora-A expression by introduction of Aurora-shRNA. Oligonucleotides corresponding to mouse Aurora-A were synthesized (shRNA #1, corresponding to amino acids 55-74 of the coding region, with a forward sequence of 5 0 -GATCCCTTCGGTCCGAAACGCGTCTTTCAAGAGAA-GACGCGTTTCGGACCGAATTTTTA-3 0 , and a reverse sequence of 5 0 -AGCTTAAAAATTCGGTCC-GAAACGCGTCTTCTCTTGAAAGACGCGTTTCGGACCGAAGG-3 0 ; shRNA #2, corresponding to nucleic acids 104-123 of the coding region, with a forward sequence of 5 0 -GATCCCTAGGATCTGCTAGCAGAGGTTCAAGAGACCACTGCTAGCA GATCCTATTTTTA-3 0 , and a reverse sequence of 5 0 -AGCTTAAAAATAGGATCTGCTAGCAGTGGTCTCTTGAACCACTGC TAGCAGATCCTAGG-3 0 ; shRNA #3, corresponding to nucleic acids 289-308 of the coding region, with a forward sequence of 5 0 -GATCCCTCCGGAAATGATTCTGAAATTCAAGAGATTTCAGAATCATTTCCGGATTTTTA-3 0 , and a reverse sequence of 5 0 -AGCTTAAAAATCCGGAAATGATTCTGAAATCTCTTGAATTTCAGAATCATTTCCGGAGG-3 0 ). The oligonucleotides were then ligated into pSUPERIOR.PURO (OligoEngine). G12V-mutated HRAS-transformed A31-1-1 cells (1-1ras1000 cells) were transfected with each shRNA, and the puromycin-resistant cells obtained. The Aurora-A expression level was determined by Western blot. (c) Normal cell morphology in HRAS transformants following #3 shRNA transfection. The transfectants were fixed with methanol and stained with first antibody (monoclonal anti-Aurora-A antibody) and second antibody (rhodamine-conjugated antimouse rabbit antibody (Chemicon)) containing DAPI (4 0 ,6-diamidino-2-phenylindole dihydrochloride) (Sigma). The stained cells were then mounted onto an anti-fade fluorescent mounting medium (DakoCytomation), and observed under a LSM510META laserscanning microscope (Carl Zeiss). The red dots represent Aurora-A and are most evident at the centrosomes. The inset shows mitotic cells with bipolar stained Aurora-A antibody. Scale bar, 20 mm. (d) A DNA histogram of HRAS transformants following #3 shRNA transfection. Cells were fixed with 50% ethanol in phosphate-buffered saline and treated with 0.125% RNase (type-II-A; Sigma) for 30 min at 371C, after which they were stained with propidium iodide (50 mg/ml). The red fluorescence of individual cells was measured using a FACSort (Becton Dickinson). (e) Depiction of transformed foci on Giemsa-stained dishes of various shRNA-and HRAS-cotransfected cells. For the shRNA experiments (reduced transformation tests), 1 mg of each oncogene-containing plasmid (10 times the dosage used for the transformation-potentiation experiments shown in Figure 1 ) was mixed with 1 mg of empty vector or 1 mg of pSUPER plasmid for each shRNA. After 2 weeks of culture, the dishes were fixed with methanol and stained with Giemsa solution. (f) Quantification of the number of transformed foci was determined using standard criteria (Kakunaga et al., 1985) . *Significant difference (Po0.001). NS, not significant Aurora-A and cancer susceptibility M Tatsuka et al (Ewart-Toland et al., 2003) . This polymorphism was also observed in the tumor specimens of the present experiment (Figure 4a ), while no differences in the sequences surrounding position 91 were observed between cancerous and noncancerous tissue in any of the patients examined. No differences in T91A-mutation frequency rates were observed between oral cancer patients (A91 -homozygote: 4/11; heterozygote: 5/11) and apparently normal volunteers (A91 -homozygote: 6/15; heterozygote: 7/15) in the present experiment (Tables 1 and 2 in supplementary information). To examine the potentiation effects of each allele (T91 and A91) with regard to transformation susceptibility, an A91-expression plasmid was created and co-transfected with G12V-HRAS into BALBc 3T3 A31-1-1 cells. A slight but significantly greater effect of the Ile31-, compared to the Phe31-, Aurora-A expression plasmid was observed with regard to HRAS-induced transformation (Figure 4b and c) . Therefore, there is a possibility that A91 allele might function to increase susceptibility to cancer development. This effect perhaps may not relate to centrosome or chromosome function, which was proposed previously (Ewart-Toland et al., 2003) . Additional studies are required to prove that the A91 allele represents a low-penetrance cancer susceptibility gene.
In this report, we propose that Aurora-A activity might modulate the oncogenic Ras signal. The precise mechanism by which this might occur remains unclear. However, it has been suggested that Aurora-B-mediated phosphorylation of MgcRacGAP might be required for Rho function during mitosis (Minoshima et al., 2003) . Similarly, Aurora-A might target small G proteinassociated GAP molecules, such as RasGAP (Tocque et al., 1997) , which mediate responsiveness to oncogenic signals generated by oncogenes, such as G12V-Ras, during interphase. Interestingly, an oncogenic Ras signal-related Ras-GAP Src homology 3 (SH3) domain has been identified as an Aurora-binding site (Gigoux et al., 2002) . In addition, a cytoplasmic LIM-domain protein, Ajuba, was identified as an Aurora-A activation protein (Hirota et al., 2003) . Ajuba interacts with Grb2 and affects Ras signaling (Goyal et al., 1999) , and, presumably, the Aurora-A/Ajuba complex also modulates Ras signaling.
Aurora-A is thought to play a role in human carcinogenesis by activation of the Ras-related growthsignaling cascade, through a loss of maintenance of centrosome and chromosome number. In normal cells, Aurora-A regulates centrosome microtubule function during mitosis. Thus, Aurora-A activity is important in ensuring accurate chromosome segregation into daughter cells. When normal cells enter the G 1 phase, Aurora-A is degraded. However, in cancer cells, Aurora-A, which is overexpressed during mitosis, is completely not destroyed when the cell enters the G 1 phase of the cell cycle (manuscript in preparation). We suggest that cancer cells might possess a mechanism by which to produce destruction-resistant Aurora-A. Furthermore, overexpression of Aurora-A during mitosis might cause mitotic failure, while overexpression of Aurora-A during the G 1 phase of the cell cycle might promote cancerous growth by preventing G 0 arrest via potentiation of oncogenic signals.
Aurora-A inhibitors have proven useful in cancer treatment (Harrington et al., 2004) and may have a role in cancer prevention. Amplification of the Aurora-A Figure 3 Gene amplification of Aurora-A in human oral gingival and tongue cancer. (a) Southern blot analysis of normal (N) and tumor (T) tissue DNA from various oral cancer patients with gingival tumors (G) or tongue tumors (T). Genomic DNA was extracted from freshly frozen samples obtained by biopsy. The DNA was digested with HindIII, loaded onto agarose gel (10 mg per lane), and then transferred to a Nylon membrane (Bio-Rad). Southern blot hybridization was performed using human Aurora-A cDNA (whole coding region), or a nonamplified pseudogene (1.3-kb HindIII fragment). Quantification was performed using the lumino-imaging analyzer BAS-2000 (Fuji Film) . Four Aurora-A-hybridized bands appeared (a: 10 kb; b: 5.5 kb; c: 0.678 kb; d: 0.41 kb). Differences in the signal intensity of each band, as well as an unamplified pseudogene band (e: 1.3 kb), were normalized to the signal ratio of normal human diploid fibroblasts (NHDF), and used to estimate the number of gene copies. (b) Expression levels of Aurora-A mRNA measured by quantitative RT-PCR. mRNA was extracted from the samples and quantitative RT-PCR was carried out as described previously (Katayama et al., 1999) . The data were normalized to the value obtained for NHDF. (c) Genomic Southern blot analysis of tongue, lymphocyte, and salivary gland samples from patient #9
Aurora-A and cancer susceptibility M Tatsuka et al gene is likely involved in some cases of human cancer. Although gene amplification does not necessarily result in increased Aurora-A protein levels in all cancer cell lines (our unpublished data), amplification of the Aurora-A gene might indicate susceptibility to carcinogenesis. Figure 4 Effect of T91A polymorphism of Aurora-A on HRAS-induced transformation in vitro. (a) Aurora-A position 91-surrounding DNA sequences in normal and tumor tissue samples from various patients. The extracted genomic DNA was used as a template in order to amplify sequences surrounding amino-acid position 91 of Aurora A (performed using a primer set with a sense sequence of 5 0 -TCCAGTTG-GAGGTCCAAAACGTGTTCTCGTGACT-3 0 , and an antisense sequence of 5 0 -TTCTGCTTCTGATTCTGAACCGGCTTGTGACTGG-3 0 ). The PCR products (180 bp) were isolated from the agarose gel and sequenced using the dye-termination method (ABI) with the antisense primer. W represents A or T. (b) Depiction of transformed foci on Giemsa-stained dishes of T91-or A91-Aurora-A and HRAS co-transfected cells. pcDNA3FLAG-A91-Aurora-A was produced by PCR-generated mutagenesis of the T91-Aurora-A (HeLa type) construct. The experimental conditions used for transfection and Western blot were the same as described in the legend of Figure 1b. (c) Quantification of the number of transformed foci was determined using standard criteria (Kakunaga et al., 1985) . *Significant difference (Po0.05)
